The shares are listed on the NYSE

Davis Polk advised the underwriters in connection with the $3.1 billion secondary offering of 790,554,820 ordinary shares, including ordinary shares in the form of American depositary shares each representing two ordinary shares, of Haleon plc by Pfizer Inc. The ordinary shares are admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of the London Stock Exchange. The American depositary shares are listed on the New York Stock Exchange (NYSE).

Concurrent with completion of the secondary offering, Haleon plc has also completed the repurchase of 102,272,727 ordinary shares from Pfizer Inc. at an aggregate price of £315 million.

Haleon is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands include Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.

The Davis Polk capital markets team included partners Connie I. Milonakis and Dan Hirschovits and associates Serdar Inci, Francesco Mancuso and Vivek Thanki. The tax team included partner Dominic Foulkes and associates Kelli A. Rivers and Patrick O’Donovan. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the London and New York offices.